liu.seSearch for publications in DiVA
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • oxford
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
The potentiality of histone deacetylase inhibitors for diabetes and obesity
Linköping University, Department of Biomedical and Clinical Sciences, Division of Surgery, Orthopedics and Oncology. Linköping University, Faculty of Medicine and Health Sciences.ORCID iD: 0000-0001-5394-9082
Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden.ORCID iD: 0000-0002-0463-1518
2020 (English)In: Histone Modifications in Therapy / [ed] Pedro Castelo-Branco, Carmen Jeronimo, San Diego, United states: Elsevier, 2020, p. 361-371Chapter in book (Other academic)
Abstract [en]

Diabetes, obesity, and metabolic syndrome represent the current global epidemic. In spite of the continuous development of related pharmaceuticals, complications of these conditions lower the patient's life quality and cause a burden on the health economy. Histone deacetylase inhibitors are slowly emerging as a line of management for several medical conditions. Many studies have described their potential role in diabetes, in terms of enhancing insulin secretion and decreasing insulin resistance. In obesity, these agents showed a very interesting role in converting white fat cells to their brown counterpart, as well as shifting the metabolic pathways toward less adiposity. Although these effects are characterized at the cellular and preclinical levels, few clinical studies have been reported. This chapter includes an overview of the relation between histone deacetylation and the development of diabetes and obesity, as well as the possible future role of histone deacetylase inhibitors in the management of these conditions.

Place, publisher, year, edition, pages
San Diego, United states: Elsevier, 2020. p. 361-371
Series
Translational Epigenetics ; 20
Keywords [en]
Obesity, Diabetes, Metabolic syndrome, Epigenetic, Epigenetic modifiers, Histone deacetylase inhibitor, Selective histone deacetylase inhibitor
National Category
Cancer and Oncology
Identifiers
URN: urn:nbn:se:liu:diva-184152DOI: 10.1016/C2018-0-00075-4Libris ID: 2hgkgxt2083r5g0cISBN: 9780128164228 (print)OAI: oai:DiVA.org:liu-184152DiVA, id: diva2:1649906
Available from: 2022-04-05 Created: 2022-04-05 Last updated: 2022-09-27Bibliographically approved

Open Access in DiVA

No full text in DiVA

Other links

Publisher's full textFind book at a Swedish library/Hitta boken i ett svenskt bibliotek

Authority records

El-Serafi, Ahmed TaherEl Serafi, Ibrahim Taher

Search in DiVA

By author/editor
El-Serafi, Ahmed TaherEl Serafi, Ibrahim Taher
By organisation
Division of Surgery, Orthopedics and OncologyFaculty of Medicine and Health Sciences
Cancer and Oncology

Search outside of DiVA

GoogleGoogle Scholar

doi
isbn
urn-nbn

Altmetric score

doi
isbn
urn-nbn
Total: 33 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • oxford
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf